Denosumab improves bone mineral density and microarchitecture in rheumatoid arthritis: randomized controlled trial by HR-pQCT

ConclusionDenosumab may be recommended for patients with RA treated with csDMARDs to increase BMD and improve bone microarchitecture.
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research